A 34-year-old man with 22q11.2 deletion syndrome (DiGeorge syndrome) concurrently suffered from myopathy and eosinophilic pneumonia shortly after receiving daptomycin (DAP) for right-sided infective endocarditis. The simultaneous occurrence of these phenomena in relation to DAP therapy has not been previously well described. An allergic reaction was suspected as a possible etiology of these DAP-related complications. This case highlights the need for close observation in order to detect both musculoskeletal and respiratory disorders from the start of DAP therapy. Physicians should pay more attention to this new drug, which is expected to be frequently used in various clinical settings.
Introduction
Daptomycin (DAP) is a novel cyclic lipopeptide with an excellent spectrum for Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (1) . Recent guidelines recommend the use of DAP to treat various infections of high grade (2) , and this drug has become widely applied in various clinical situations.
Musculoskeletal injury is a well-known adverse event of DAP therapy. In phase III clinical trials, serum creatine kinase (CK) elevation has been reported to occur in 2.8% of patients receiving DAP, with myopathic symptoms occurring in 0.2% of cases (3) . Subsequently, rates of DAP-related serum CK elevation to be up to 6 .7% have been demonstrated (4) (5) (6) (7) .
The development of eosinophilic pneumonia (EP) is another possible side effect of treatment with DAP. Although there were no cases of respiratory toxicity in a previous large-scale study (4) , the first case was reported in 2007 (8) , followed by an increasing number of DAP-induced EP patients.
Notably, the coexistence of these two important adverse events of DAP therapy has not been previously documented.
We herein report a case in which myopathy and EP concurrently developed shortly after the initiation of DAP therapy.
Case Report
A 34-year-old man (height: 164 cm, weight: 90.8 kg, body mass index: 31.5) who had been genetically diagnosed with 22q11.2 deletion syndrome (DiGeorge syndrome) visited our department complaining of a persistently high fever lasting for a few days. Due to extreme tetralogy of Fallot, the patient had undergone cardiac surgery five times in total. Under a diagnosis of bronchial asthma, he was prescribed inhaled budesonide and oral montelukast. He had no history of dyslipidemia or treatment with statins; however, he was a current smoker (30 cigarettes per day). A physical examination performed upon arrival revealed a cardiac systolic murmur (Levine 4/6), while a laboratory examination showed a high inflammatory state (white blood cell count: 9,800/μL, C-reactive protein: 15.9 mg/dL, procalcitonin: 1.31 ng/mL); therefore, the patient was admitted for further investigation and treatment.
The next day, a blood culture was positive for Grampositive cocci, and DAP was empirically administered at a dose of 700 mg (approximately 8 mg/kg/day). Based on a positive finding for multiple emboli in the peripheral fields of the bilateral lungs on computed tomography (CT), a diagnosis of right-sided infective endocarditis (IE) was suspected. Although transthoracic and transesophageal echocardiograms did not show any characteristic findings, a contrast-enhanced CT heart scan successfully visualized an area of vegetation in the right ventricular outflow tract of the homograft measuring 14 mm in size. Notably, there were no such lesions on a previous CECT heart scan, and fluorodeoxyglucose-positron emission tomography demonstrated a high uptake at the corresponding site. According to these findings, the lesion was considered to be a newly formed site of infective vegetation, and a definitive diagnosis of IE (two major Duke's criteria) was made. After the pathogen was confirmed to be methicillin-sensitive S. aureus (MSSA), the antibiotic therapy was changed to a combination of cefazolin, gentamycin and rifampicin. In total, three doses of DAP were given at that time, without any adverse events.
Although the patient's fever disappeared, follow-up blood cultures were negative and the serum inflammatory markers decreased to almost the normal levels, a follow-up contrastenhanced CT heart scan performed two weeks after the initiation of definitive therapy showed that the area of vegetation had not decreased. Therefore, a high dose of DAP (10 mg/kg, 875 mg) was added to the antibiotic regimen in expectation of a high degree of permeability into biofilms. During the evening of that day (within one-half day after the start of DAP therapy), the patient became aware of myalgia and weakness in the bilateral forearms. A high-grade fever and muscle stiffness appeared the following day, and the administration of DAP was immediately discontinued. DAP had been given twice by that time. However, the patient's fever persisted, and the serum levels of CK and Creactive protein remained elevated at a peak of 1,754 IU/L and 12.18 mg/dL, respectively (on day 3 of DAP administration). Although the patient's muscle symptoms and laboratory abnormalities resolved quickly after discontinuing the dose of DAP, he subsequently developed a cough with mild hypoxemia. Chest CT performed on day 7 of DAP treatment showed a newly emerged site of consolidation in a peripheral field of the right upper lobe. Although a bacterial culture of the purulent sputum was negative for any pathogenic organisms, Giemsa staining revealed the infiltration of inflammatory cells, including a substantial amount of eosinophils (approximately 11%). Mild eosinophilia (serum eosinophil count: 510/μL on day 8 of DAP treatment) was also noted. Based on the patient's clinical course and findings, the potential involvement of DAP-induced EP was considered. His respiratory function was relatively stable; therefore, further investigation with bronchoalveolar lavage (BAL) was not performed. His respiratory symptoms gradually resolved, without the systemic administration of corticosteroids, and the CT findings gradually improved, almost disappearing after six weeks. The patient's clinical course is shown in the Figure. The results of a drug lymphocyte stimulation test for DAP were later confirmed to be negative.
In addition to the above symptoms, the patient simultaneously suffered from nasal congestion. Consequently, CT demonstrated deteriorating mucosal hypertrophy of the nasal cavity and sinus, and eosinophilic sinusitis was suggested on Hansel staining of the nasal discharge. A nasal spray containing a corticosteroid (mometasone) was subsequently prescribed, and the nasal obstruction gradually improved.
Despite the administration of antibiotic therapy for 10 weeks, the site of infective vegetation did not disappear, and cardiac surgery was ultimately performed to remove the vegetation and replace the pulmonary artery with a prosthetic graft. No recurrence of EP was observed postoperatively.
Discussion
We herein presented the case of a patient who concurrently suffered from both myopathy and EP, and possibly eosinophilic sinusitis, shortly after the initiation of DAP therapy. DAP was given in expectation of high permeability into the biofilm formed at the site of vegetation (9) . Myopathy and EP are well-known adverse effects of DAP treatment; however, the simultaneous occurrence of these two events has not been previously documented in detail.
DAP is a well-known etiology of drug-induced myopathy (10) . DAP binds to bacterial membranes, inducing depolarization of the membrane potential, thus leading to a bactericidal effect. Similarly, DAP is thought to cause leakage of intracellular CK by causing membrane disruption of muscle fibers (4) . The accumulation of DAP and/or an increase in the trough concentration of the drug have been shown to be primarily related to musculoskeletal injury (11, 12) . In most cases, the onset of myopathic symptoms or CK elevation usually occurs more than one week after initiating DAP therapy (6, 13) . Although some studies have demonstrated the early onset of musculoskeletal events after only a few doses of DAP, Edwards et al. described a case of side effects following a single dose of the drug (14), Colomba et al. reported a case involving two doses (15) and Patel et al. described a case involving three doses (16) .
EP is another possible adverse effect of DAP administration in the present case. Although it can be difficult to make a definitive diagnosis without performing BAL or a lung biopsy, we are confident that our patient suffered from DAPinduced EP. In order to clarify the clinical characteristics of DAP-induced EP, we performed a literature review. Consequently, the data for 25 previous cases and the present case are summarized in the Table (8, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The average age of the patients was 64 years (range: 26 to 87 years), and men were predominant (88%, 22 of 25 patients). No patients had an apparent history of bronchial asthma, except for our patient (data not shown in the table). The dose of DAP varied, although EP occurred in the majority of cases (85.7%, 18 of 21 cases) at the currently recommended dose (less than 6
Figure. Clinical course of daptomycin-induced eosinophilic pneumonia and creatinine kinase elevation in the present case. The day on which the second course of daptomycin (DAP) was administered is set as Day 1 in this figure. On admission, the serum creatinine kinase (CK) level was within the normal range and there were no relevant findings in the lungs or sinuses. DAP was first administered for three days as an empirical therapy. Three weeks later, immediately after the administration of the second course of DAP, serum CK elevation accompanied by myopathic symptoms appeared. The patient's condition promptly improved only after withdrawing the dose of DAP, with a peak level on day 3. Simultaneously, consolidation appeared in the right upper lobe, which also spontaneously reduced in size and finally vanished following the withdrawal of DAP. The lesion was considered to be associated with eosinophilic pneumonia, with evidence of a large amount of eosinophils in the sputum. In parallel with these events, a significant amount of mucus, which was not observed prior to DAP therapy, was found to have accumulated on CT. The mucus also disappeared gradually following the cessation of DAP. mg/kg). The dose administered in the present case was the second largest (875 mg, 10 mg/kg). The duration to the onset of EP in previous cases was at least one week. The exact pathophysiology of DAP-induced toxicity remains unknown; however, the accumulation of DAP in tissues is thought to be one pathogenic mechanism (8, 11, 17) . It is well known that the long-term administration of DAP results in the recruitment of T-helper 2 lymphocytes and subsequent release of interleukin-5, which induces the migration of eosinophils (27) , thereby causing cellular and/or epithelial damage (8, 17, 28) . Therefore, it usually takes at least one week for pulmonary complications to appear. However, as described in this report, our patient developed respiratory symptoms after only two doses of DAP, and the above theory cannot be simply applied in the present case.
The administration of high-dose treatment (10 mg/kg of DAP) is be another possible reason for the early onset observed in this case. However, the safety (29-32) and utility (31) of administering such a high dose have been previously demonstrated, and the dose of DAP applied in previous cases of early-onset myopathy was 4 to 5 mg/ kg (14, 16) . Therefore, we do not consider that the patient's condition was merely due to a problem with the dose.
Rather, considering the rapid onset noted in this case, the involvement of an allergic mechanism is suspected. The patient was first given DAP empirically for three days (three weeks prior to the events) and may have been sensitized to DAP at that time. Patients with obesity, diabetes mellitus, renal insufficiency and electrolyte abnormalities are considered to be at higher risk for musculoskeletal injury (33) . Of these conditions, obesity (BMI: 31.5) and electrolyte abnormalities (hypocalcemia and hypomagnesemia) may have played a role as predisposing factors in our patient. In summary, this case indicates the importance of monitoring the serum CK level and detecting the emergence of new respiratory symptoms from the start of DAP therapy. When myopathy or serum CK level elevation is noted in patients receiving DAP, lung involvement should also be considered. Hence, more attention should be paid to this relatively new drug, which is expected to be used in various clinical settings. 
Recover
The patients were mostly febrile (76.9%, 10 of 13 cases in published cases) and peripheral eosinophilia was commonly seen with various significance (82.6%, 19 of 23 cases). Radiological findings of the cases were consistently characteristic of the general manifestation of EP; I.e., patchy bilateral infiltrates in peripheral lung fields. BAL was performed in most cases and the fluid examination results showed a wide range of eosinophils (9 to 81%). Lung biopsy was performed in at least 7 cases and was of great diagnostic value in all cases. DAP re-challenge was undertaken only in three patients, and those patients developed acute and severe respiratory failure. of note, Although at least five patients were managed with a mechanical ventilator and two patients (cases 8, 9) became chronically steroid-dependent, all of the patients finally recovered. Seven of the cases (26.9%) were treated only by withdrawal of DAP, and two cases including our case were given inhaled corticosteroid therapy.
